Strekin STR001 for Sudden Sensorineural Hearing Loss
Also known as: STR001, STR001-IT, STR001-ER, STR001-IT and STR001-ER, str001-it-and-str001-er, NCT03331627, 2017-000242-22
Strekin AG
STR001 treatment regimen combining intratympanic thermogel (STR001-IT) and oral tablets (STR001-ER), evaluated on top of standard of care for adults with sudden sensorineural hearing loss.
Verified as a real Strekin-sponsored Phase 3 sudden-sensorineural-hearing-loss program from ClinicalTrials.gov and ICH GCP registry evidence. The trial evaluated STR001 intratympanic thermogel and oral tablets on top of standard of care, enrolled 165 adults, and completed in February 2020. No public results publication or current active company development signal was confirmed in this pass; the former Strekin domain currently resolves to a parked-domain sale page, so the record should be treated as a verified historical/completed program rather than an active pipeline asset.